HIGHLIGHTS
SUMMARY
Allogeneic hematopoietic stem_cell transplantation (HSCT) is a curative procedure for selected malignant and nonmalignant hematological diseases. Non-relapse-related adverse outcomes include toxicity of peritransplant therapies and graft-versus-host disease (GVHD) due to the attack of recipient`s tissue by donor effector cells. The authors report the case of a patient who received an HSCT from an HLA-matched unrelated donor with a known history of chronic lymphocytic thyroiditis, also known as "Hashimoto`s thyroiditis" (HT). He then received consolidation with cyclophosphamide 70 mg/m2 and total body irradiation (TBI, 1000 cGy) followed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.